Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70064 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Giovanni Caponetti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Office and R&D, Zambon S.p.A., Bresso, Italy. Hauptthemen laut MEDLINE: Antifungal Agents, Asthma, Voriconazole. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The aim of this study was to evaluate safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of a novel inhaled formulation of voriconazole (ZP‐059). In the single ascending dose part, 4 cohorts of 6 healthy subjects received one dose of inhaled voriconazole (5–40 mg). In the multiple ascending dose part, 3 cohorts of 6 subjects with mild asthma received voriconazole 10 mg twice daily [BID], 20 mg BID or 40 mg once daily. In the 2‐period crossover part, 16 subjects with mild to moderate asthma each received one dose of inhaled voriconazole 20 mg and one dose of oral voriconazole 200 mg. A bioanalytical method was developed and validated to simultaneously determine concentrations of voriconazole and its metabolite N‐oxide voriconazole in serum and sputum. Inhaled voriconazole was well tolerated with no treatment emergent adverse events (TEAEs) leading to treatment discontinuation. The PK profile of inhaled voriconazole showed rapid absorption, apparent greater than proportional increase in exposure with increasing dose, a consistent half‐life across dosing, and large clearance and volume of distribution. Following repeat administration limited accumulation was observed. Systemic exposure following inhaled voriconazole was much lower than following oral voriconazole. Serum data confirmed that voriconazole was extensively metabolized also when administered by inhalation. Sputum data following inhaled voriconazole were limited but demonstrated increasing exposure with increasing dose. The current study shows the newly developed dry powder inhaled formulation of voriconazole to be safe and well tolerated, providing a possible improved treatment approach for patients affected by allergic bronchopulmonary aspergillosis. Trial Registration: ClinicalTrials.gov ID: NCT04229303
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Medical Office and R&D, Zambon S.p.A., Bresso, Italy.
- Medicines Evaluation Unit Ltd. (MEU), The Langley Building, Manchester, UK.
- University of Manchester, Manchester University NHS Hospital Trust, Manchester, UK.
ORCID-Profile: Daniele Colombo
Zitieren
APA
Caponetti, G., Sala, F., Cervetti, A., Colombo, D., Tiberio, E., & Singh, D. (2025). Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70064
Vancouver
Caponetti G, Sala F, Cervetti A, Colombo D, Tiberio E, Singh D. Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70064
BibTeX
@article{Caponetti2025,
author = {Caponetti, Giovanni and Sala, Federica and Cervetti, Antonio and Colombo, Daniele and Tiberio, Elena and Singh, Dave},
title = {Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70064}
}
EUVIMED